These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2498537)

  • 21. Hemophilia treatment in historical perspective: a review of medical and social developments.
    Rosendaal FR; Smit C; Briët E
    Ann Hematol; 1991 Feb; 62(1):5-15. PubMed ID: 1903310
    [No Abstract]   [Full Text] [Related]  

  • 22. Clotting factor concentrates for resistant haemophilia.
    Bloom AL
    Br J Haematol; 1978 Sep; 40(1):21-7. PubMed ID: 361064
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hemophilia and HTLV-III infection].
    Lechler E
    Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current status and future prospects of hemophilia treatment].
    Lopaciuk S
    Acta Haematol Pol; 1995; 26(2 Suppl 1):44-55. PubMed ID: 7653234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of a cooperative programme of profilactic treatment for haemophilia A and B (author's transl)].
    Sangre (Barc); 1978; 23(5B):780-92. PubMed ID: 725718
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety of therapeutic products used for hemophilia patients.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1988 Jul; 37(29):441-4, 449-50. PubMed ID: 3134602
    [No Abstract]   [Full Text] [Related]  

  • 27. Leads from the MMWR. Safety of therapeutic products used for hemophilia patients.
    JAMA; 1988 Aug; 260(7):901-3. PubMed ID: 3398188
    [No Abstract]   [Full Text] [Related]  

  • 28. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 29. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
    Lechner K; Niessner H; Bettelheim P; Deutsch E; Fasching I; Fuhrmann M; Hinterberger W; Korninger C; Neumann E; Liszka K
    Thromb Haemost; 1983 Aug; 50(2):552-6. PubMed ID: 6314582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
    Kunst VA; Nováková IR; Haanen C
    Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
    Weisser J
    Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 35. [New strategies of treatment of hemophilia].
    Yoshioka A
    Rinsho Ketsueki; 2000 May; 41(5):365-9. PubMed ID: 10879092
    [No Abstract]   [Full Text] [Related]  

  • 36. [Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].
    Tavares A; Galvão M
    Acta Med Port; 1992 Dec; 5(11):587-90. PubMed ID: 1293952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood safety and the choice of anti-hemophilic factor concentrate.
    Valentino LA; Oza VM
    Pediatr Blood Cancer; 2006 Sep; 47(3):245-54. PubMed ID: 16724312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased helper-suppressor cell ratios following treatment with blood products: factor VIII and IX concentrates and fresh frozen plasma.
    Ragni MV; Lewis JH; Spero JA; Bontempo FA; Rabin BS
    Scand J Haematol Suppl; 1984; 40():371. PubMed ID: 6236552
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy of factor VIII deficiency.
    Gill JC
    Semin Thromb Hemost; 1993; 19(1):1-12. PubMed ID: 8456319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy for AHF and PTC hemophilia. II.
    Seeler RA
    IMJ Ill Med J; 1970 Jun; 137(6):598-602 passim. PubMed ID: 4393113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.